A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR)

Heart failure due to systemic left ventricular systolic dysfunction

Base Period: Change from baseline to Week 16 in log-transformed n-terminal pro-brain natriuretic peptide (NT-proBNP), Extension Period: Percentage of participants with one or more adverse events (AE), Extension Period: Percentage of participants who discontinued study drug due to an AE

Base Period: Change from baseline to Week 52 in log-transformed NT-proBNP, Base Period: Time from randomization to the first event of cardiovascular (CV) death, heart failure hospitalization (HFH), or worsening of heart failure (HF) without hospitalization, Base Period: Percentage of participants with one or more adverse events (AE), Base Period: Percentage of participants who discontinued study drug due to an AE, Base Period: Area under the curve from time 0-24 hours post-dose (AUC0-24) of plasma vericiguat, Base Period: Half-life (t1/2) of vericiguat in plasma, Base Period: Oral clearance (CL/F) of plasma vericiguat, Extension Period: Change from extension period baseline to extension period Week 16 in NT-proBNP

No related papers found yet.

Belgium, Croatia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Netherlands, Poland, Portugal, Spain, Sweden